ReNeuron Group plc Block listing application (3900R)
March 01 2023 - 2:01AM
UK Regulatory
TIDMRENE
RNS Number : 3900R
ReNeuron Group plc
01 March 2023
ReNeuron Group plc
("ReNeuron" or "the Group" or the "Company")
Block listing application
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell
derived exosome technologies , announces that an application has
been made to the London Stock Exchange for a block listing of
securities in respect of 5,254,368 Ordinary Shares of 1p each (the
"New Ordinary Shares") to be admitted to trading on AIM. It is
expected that admission will become effective on or around 2 March
2023.
The New Ordinary Shares will be issued when necessary, in order
to satisfy the issue of shares pursuant to the exercise of options
issued under the Company's share schemes. When issued, the New
Ordinary Shares will be credited as fully paid and will rank pari
passu in all respects with the existing Ordinary Shares of 1p each
in the capital of the Company.
ENDS
Enquiries:
ReNeuron www.reneuron.com/investors
Iain Ross, Chairman Via Walbrook PR
John Hawkins, Chief Financial Officer
Liberum Capital Limited (NOMAD and
Joint Broker)
Phil Walker (Investment Banking)
Richard Lindley (Investment Banking)
Ben Cryer (Investment Banking) +44 (0)20 3100 2000
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
Paul McManus / Alice Woodings +44 (0)7980 541 893 / +44 (0)7407 804
654
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived,
exosome-based, drug delivery platform with customisable cellular
targeting capabilities for the delivery of complex drug
modalities.
Through the generation of several unique and scalable exosome
producer cell lines, our CustomEX(TM) platform can be optimised for
specific tissues targets and payloads leading to improvements in
therapeutic outcome and a reduction in off-target effects. ReNeuron
offers a delivery mechanism for a variety of payloads such as
siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform, the Company can make allogeneic tissue cells of choice
and has the potential to produce exosomes with tissue specific
targeting ability.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ALSQVLFLXLLBBBX
(END) Dow Jones Newswires
March 01, 2023 02:01 ET (07:01 GMT)
Reneuron (AQSE:RENE.GB)
Historical Stock Chart
From May 2024 to Jun 2024
Reneuron (AQSE:RENE.GB)
Historical Stock Chart
From Jun 2023 to Jun 2024